EAM Global Investors’s Adicet Bio ACET Stock Holding History

EAM Global Investors’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,763	Closed	-$1.84M	–	181
2022 Q1	$1.84M	Buy	+5,763	New	+$1.33M	0.34%	158

Other funds holding ACET

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EAM Global Investors's ACET Position: Q2 2022 in Review

EAM Global Investors sold out of Adicet Bio (ACET) in Q2 2022, closing a stake of 5,763 shares — an estimated $1.84M sold.

EAM Global Investors first reported a position in ACET in Q1 2022 and held it in 1 quarter. The position peaked at $1.84M in Q1 2022. 101 funds tracked by Wall St. Rank hold ACET as of Q2 2022.

EAM Global Investors reported no remaining Adicet Bio position as of Q2 2022 after selling out during the quarter.
EAM Global Investors sold 5,763 Adicet Bio shares in Q2 2022, an estimated $1.84M.
EAM Global Investors first reported a position in Adicet Bio in Q1 2022 and held it in 1 quarter.
EAM Global Investors's Adicet Bio position peaked at $1.84M in Q1 2022.
101 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2022.

Based on EAM Global Investors's 13F filing for Q2 2022, filed 12 Aug 2022.